Yen-Hsiang Huang

4PUBLICATIONS
10CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jun 08, 2026
Afatinib Versus Osimertinib as First-Line Treatment for Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A 3-Year Follow-Up Overall Survival Analysis.

|Jan 08, 2025
Osimertinib as Second- and ≥Third-Line Treatment in Advanced and Recurrence EGFR-Mutant NSCLC Patients Harboring Acquired T790M Mutation.

Mu-Han Peng, Yen-Hsiang Huang, Kuo-Hsuan Hsu

|Nov 01, 2024
Real-world clinical efficacy of bevacizumab biosimilar in patients with advanced non-small-cell lung cancer.

Wei-Fan Ou, Kuo-Hsuan Hsu, Jeng-Sen Tseng

|Sep 30, 2024
Using a Polygenic Risk Score to Improve the Risk Prediction of Non-Small Cell Lung Cancer in Taiwan.

Po-Hsin Lee, I-Chieh Chen, Yi-Ming Chen

Pageof 1

Frequent Collaborators

3 joint publications

Kuo-Hsuan Hsu

2 joint publications

Jeng-Sen Tseng

1 joint publications

Po-Hsin Lee

1 joint publications

I-Chieh Chen